Twist Bioscience will leverage its antibody optimization platform to help develop further autoimmune and inflammatory candidates for Pandion Therapeutics. The two firms have completed an initial project using Twist’s antibody optimization platform based on DNA sequencing technology and will now collaborate on further antibodies for autoimmune regulation. Twist Biopharma – a division of California-based Twist Bioscience – CEO Emily Leproust said the deal with Pandion “is an excellent example of how our antibody optimization solution can change the discovery and…